CMV-TCR-T Cells for Refractory CMV Infection After HSCT

Allogeneic Hematopoietic Stem Cell Transplantation Clinical Trial

Official title:

A Study of CMV-TCR-T Cells in the Treatment of Refractory CMV Viremia After HSCT

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05089838
• Other study ID #: 2020PHD014-001
• Status: Recruiting
• Phase: Phase 1
• Start date: January 6, 2021
• Est. completion date: October 2023

Study information

• Verified date: October 2021
• Source: Peking University People's Hospital
• Contact: Lanping Xu, PhD,MD
• Phone: 86-010-88324671
• Email: lpxu_0415[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.

Description:

CMV infection is a major and potentially life-threatening complication after allogenic hematopoietic stem cell transplantation (allo-SCT). Pharmacotherapy with ganciclovir and foscarnet remains the mainstay of treatment and has significantly improve clinical results, however, it is unsatisfactory owing to toxicity, limited efficacy and risk of developing resistance.

In recent years, adoptive T cell therapy has been proposed as an alternative option for CMV infection after allo-SCT. However, patients with transplants from CMV-negative donors are at highest risk, and an adoptive therapy is missing because CMV-specific T cells are not available.

CMV TCR-transduced donor-derived T Cells (CMV-TCR-T cells) is an attractive strategy to specifically redirect T-cell immunity toward CMV. In this prospective clinical phase I trial, we propose to evaluate the safety and efficacy of stem cell donor-derived CMV-TCR-T cells for patients with refractory CMV infection after allo-SCT. Donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: October 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) who receive haploid allogeneic hematopoietic stem cell transplantation, pre-transplantation assessment =CR2;

2. Age 18-60, including boundary value, gender unlimited;

3. Refractory CMV infection occurred in the early stage of transplantation : After 2 weeks of standard antiviral treatment, the CMV DNA copy number continued to be =1000 copies/mL, and the CMV DNA copy number at the beginning of the treatment decreased by <log10 ;

4. The transplant donor's HLA-A matching is one of 2402, 0201 or 1101, and the physical examination is qualified;

5. ECOG = 3, estimated life expectancy> 3 months;

6. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.

Exclusion Criteria:

1. Patients with active aGVHD III-IV and / or mild and severe cGVHD;

2. Have received cell therapy such as DLI, CTL, CAR-T, NK or participated in any other clinical research on drugs and medical devices;

3. Patients who have developed CMV disease;

4. patients with organ failure:

• Heart: NYHA heart function grade IV;

• Liver: Grade C that achieves Child-Turcotte liver function grading;

• Kidney: kidney failure and uremia;

• Lung: symptoms of respiratory failure;

• Brain: a person with a disability;

5. Pregnant or lactating women;

6. The researchers found that it was unsuitable for the recipients to be enrolled.

Related Conditions & MeSH terms

• Allogeneic Hematopoietic Stem Cell Transplantation
• CMV Infection
• Cytomegalovirus Infections
• Infections

Intervention

Biological:
• CMV-TCR-T cells
Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).

Locations

Country	Name	City	State
China	Peking University Institute of Hematology,People's hospital Peking University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Xiao-Jun Huang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events	Percentage of participants with adverse events	3 months
Secondary	Changes of CMV-DNA copies	Changes of CMV-DNA copies	3 months
Secondary	CMV-specific immunity reconstitution	In vivo persistence of the infused CMV-TCR-T cells and reconstitution of CMV-specific immunity	3 months